MaxCyte Inc (MXCT) Ord USD0.01 (DI)
- Add to watchlist
- Create an alert
- This stock can be held in a
323.00p
330.00p
420.00p
£348.09 million
323.00p
322.00p
256.00p
n/a
23.00p (6.65%) Previous:
23.00p
5,692
n/a
750
Performance
1 week 1W | 1.2% | 1 year 1Y | 13.16% |
---|---|---|---|
1 month 1M | 25.95% | 2 years 2Y | 20.48% |
3 months 3M | 4.43% | 3 years 3Y | 55.04% |
6 months 6M | 1.54% | 5 years 5Y | 180.85% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue ($m) | 41.29 | 44.26 |
Profit before tax ($m) | (37.92) | (23.57) |
Adjusted EPS (¢): | (37.00) | (54.87) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: US dollar
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
MaxCyte upgrades revenue guidance after operational review
9 December 2024 08:55
-
MaxCyte appoints new chief commercial officer
10 October 2024 13:23
-
MaxCyte enters licence agreement with Kamau Therapeutics
16 September 2024 11:22
-
Holding(s) in Company
19 December 2024 16:26
-
Holding(s) in Company
18 December 2024 15:31
-
Holding(s) in Company
10 December 2024 17:16
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.